gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · BOLTHealthcarePharmaceuticals

Bolt Biotherapeutics, Inc. Common Stock (BOLT)

$6.54−0.46%
Close Nov 4, 2026 · split-adjusted
Oct 30, 2026$6.59▲ 18.10% in range
Nov 3, 2025Low $3.18 · High $7.09Oct 30, 2026
What changed · written from our data
As of Nov 4, 2026

Bolt Biotherapeutics closed at $6.54 on Nov 4, down 0.46%, 7.8% below its 52-week closing high. Volume of 85.8K shares was 0.12× its 20-day average (below normal).

Split-adjusted performance: +86.3% over one month, +42.5% over six months, +17.2% over one year.

In the quarter ended Jun 30, 2026, revenue was $5K, down 99.7% from a year earlier, with a net margin of -154400.0%.

Short interest was 15.8K shares at the Oct 15 settlement, down 38.8% from the prior report (1.1% of float, 1.0 days to cover).

Market cap$15.4M2.4M shares
Revenue · quarter$5.0K−99.7% YoY
Diluted EPS$-4.57—
P/E · TTM—P/S 3.3×
Net margin-154,400.0%Gross 100.0%
Dividend yieldNone
52-week range3.18 – 7.09−7.8% from high
Volume85.8K0.12× 20-day avg
Volatility · 60d112.3%Annualised
Short % of float1.1%1.0 days to cover
Net cash$17.6MCash $17.6M
Next earnings—Not scheduled
Split-adjusted performance
1W −0.6%1M +86.3%3M +69.0%6M +42.5%YTD +19.6%1Y +17.2%3Y −67.0%5Y −97.3%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum91
Revenue growth10
Net margin1
Value (low P/E)—
Size19

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short15.8K−38.8% vs prior
Days to cover1.0Settled Oct 15
% of float1.1%
Short vol. 10d41.6%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
BOLTBolt Biotherapeutics$6.54−0.46%+42.5%−99.7%−154400.0%—$15.4M
CTXRCitius Pharmaceuticals$0.5510−3.87%−17.3%—−593.3%—$15.1MCompare
KYNBKyntra Bio$3.96−8.12%−44.4%———$16.0MCompare
NEUPNeuphoria Therapeutics$2.98−0.33%−44.6%———$16.1MCompare
MTEXMannatech$8.64−0.06%+77.0%+3.8%3.8%—$16.7MCompare
MRKRMarker Therapeutics$1.01+2.76%−30.8%———$16.8MCompare
ALLRAllarity Therapeutics$1.08−4.42%−27.0%———$17.2MCompare
BFRIBiofrontera$0.9038+1.56%−20.7%+32.9%−5.0%—$13.4MCompare
KTTAPasithea Therapeutics$0.53000.00%−37.6%———$17.7MCompare

News about Bolt Biotherapeutics

All news →

No recent articles focused on Bolt Biotherapeutics.

Quick answers

What does Bolt Biotherapeutics do?
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC.
What is BOLT's market cap?
$15.42M, based on the Nov 4 close of $6.54.
Does Bolt Biotherapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of BOLT is sold short?
15.8K shares, 1.1% of float, as of Oct 15, 2026.
What sector is BOLT in?
Healthcare, in the Pharmaceuticals industry.

About Bolt Biotherapeutics

Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.

HQ: Redwood City, CA23 employeesListed Feb 5, 2021boltbio.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology